Skip to main content
Springer logoLink to Springer
. 2026 Aug 31;121(6):1227–1239. doi: 10.1007/s00395-026-01208-2

Delayed intracardiac remote ischemic preconditioning reduces infarct size in remote myocardium of pigs

Denise Traxler 1, Dominika Lukovic 1, Andreas Spannbauer 1, Ena Hasimbegovic 1, Nina Kastner 1, Martin Riesenhuber 1, Katrin Zlabinger 1, Lisa Auer 2, Noemi Pavo 1, Gerd Heusch 3, Mariann Gyöngyösi 1,✉
PMCID: PMC13782021  PMID: 42671614

Abstract

Cardioprotection induced by repetitive ischemia/reperfusion (I/R) is not confined to the ischemic region but may extend to distant myocardial territories, a phenomenon termed intracardiac remote ischemic preconditioning (icRIPC). The present study aimed to evaluate the delayed effects of icRIPC on infarct size (IS), left ventricular (LV) function (LVF), and myocardial gene and protein expression. icRIPC was induced in 13 pigs by 3 cycles of 10 min ischemia/10 min reperfusion of the left anterior descending coronary artery (LAD) (conditioning) territory, followed 24 h later by reperfused acute myocardial infarction (AMI) of the left circumflex artery (LCx) (infarcted) territory, induced by 90-min percutaneous balloon occlusion of the mid LCx followed by reperfusion (group icRIPC-AMI). Thirteen additional pigs underwent a sham icRIPC procedure followed by reperfused LCx AMI 24 h later and served as controls (group AMI). Five pigs from each group were euthanized at 3 days, and myocardial expression of nine selected genes was quantified by RT-qPCR in the distal LAD and LCx territories. Protein expression of the two significantly upregulated genes was assessed by Western blot. The remaining eight pigs in each group were followed for 1 month. At 3 days after reperfused AMI, superoxide dismutase-2 (SOD2) protein expression was increased in the infarcted LCx territory of the icRIPC-AMI group, whereas inducible nitric oxide synthase (iNOS/NOS2) protein expression was increased in the distal LAD territory. At 1 month, IS was lower in the icRIPC-AMI than in the AMI group (8.4±3.7% vs. 14.1±1.8% of LV mass, p=0.003), whereas global LVF was marginally improved. However, segmental mean contraction velocity of the infarcted lateral wall was higher in the icRIPC-AMI than in the AMI group (14.8±1.6 vs. 13.3±0.9 mm/s, p=0.026). These findings provide potentially mechanistic evidence for delayed icRIPC, characterized by reduced IS, improved regional myocardial function, and territory-specific changes in cardioprotective protein expression, and may represent an experimental correlate of the clinical phenomenon of pre-infarction angina.

Keywords: Delayed ischemic preconditioning, Cardioprotection, Intra-cardiac remote ischemic conditionng, Infarct size, Pre-infarction angina

Introduction

Recurrent episodes of transient ischemia and reperfusion (I/R), applied either in the myocardium or remotely in distant tissues or organs, increase myocardial resistance to a subsequent prolonged ischemic insult, such as acute myocardial infarction (AMI), thereby limiting infarct size (IS), attenuating adverse left ventricular (LV) remodeling, and preserving left ventricular function (LVF) [23, 25–27, 34, 42]. The cardioprotective effects induced by transient I/R occur in two temporally distinct phases: a first window of protection, which develops rapidly and persists for approximately 2–3 h after the conditioning stimulus, and a second window of protection, which emerges approximately 24 h later and may persist for up to 72 h [5, 23, 35, 41, 61]. Whereas the first window is primarily mediated by rapid activation and post-translational modification of pre-existing signaling molecules, the more sustained second window results in altered gene expression and de novo synthesis of cardioprotective proteins [5, 23].

More than 3 decades ago, Przyklenk et al. first demonstrated the cardioprotective effects of remote ischemic preconditioning (RIPC) during the first window of protection. In anesthetized dogs, four cycles of 5 min occlusion and 5 min reperfusion were applied in the left circumflex coronary artery (LCx), and 1 h later, myocardial infarction was induced by 60-min occlusion of the left anterior descending coronary artery (LAD) followed by reperfusion. This conditioning protocol significantly reduced infarction size (IS) and preserved regional contractile function in the anterior myocardium at the 4.5-h follow-up [48]. Since this seminal observation, the cardioprotective efficacy of RIPC has been confirmed across multiple experimental models and infarction settings [1, 4, 6, 34, 40, 53]. Furthermore, the concept of RIPC has been translated into the clinical setting, where transient peripheral I/R, most commonly induced by repeated inflation and deflation of a blood-pressure cuff on a limb, has been investigated as a cardioprotective strategy in patients with AMI [7, 15, 16, 31, 56, 57].

In pigs, three cycles of 10 min ischemia/10 min reperfusion (I/R) of the mid LAD without subsequent infarction were used to characterize the molecular mechanisms activated by the conditioning stimulus itself, which might otherwise be masked by the profound transcriptional changes associated with subsequent AMI [44, 45]. These experiments demonstrated that transcriptomic changes were induced not only within the ischemic territory but also in remote, non-ischemic myocardial regions, a phenomenon referred to here as intracardiac remote ischemic preconditioning (icRIPC) [44, 45]. icRIPC describes the ability of brief spontaneous or induced myocardial I/R episodes to enhance ischemic tolerance in distant, non-ischemic myocardial territories through mechanisms involving altered gene expression, post-translational protein regulation, and activation of cell-survival pathways. These findings suggest that brief episodes of myocardial I/R, clinically manifesting as stable or unstable angina or warm-up angina, may confer cardioprotection beyond the culprit-artery territory and potentially extend to the entire myocardium, a concept of particular relevance in patients with multivessel coronary artery disease [22, 27, 49].

In the present study, we provide evidence that three cycles of 10 min ischemia/10 min reperfusion of the mid LAD, without subsequent anterior infarction, confer delayed cardioprotection to the remote lateral wall subjected to LCx occlusion 24 h later, accompanied by increased superoxide dismutase (SOD2) gene and protein expression as a potential mechanistic mediator of this cardioprotective effect [5, 24].

Materials and methods

Experiments were conducted at the Animal Angiographic Laboratory of Medicopus Ltd., Kaposvár, Hungary (formerly the University of Kaposvár). All facilities met the standards of the American Association for Accreditation of Laboratory Animal Care. All animal procedures were performed in accordance with the American Heart Association’s “Position on Research Animal Use” and complied with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, National Research Council, National Academy Press, 1996). The experimental protocol was approved by the Ethics Committee on Animal Experimentation of the University of Kaposvár, Hungary (EC No. SOI/31/00889–7/2019_EPAPIR-20190925-2728; KA-2821).

Experimental protocol

A total of 26 female domestic pigs (30–35 kg) were included in the study. In 13 pigs, catheter-based, closed-chest I/R was induced by three cycles of 10 min ischemia/10 min reperfusion of the mid LAD, followed 24 h later by 90-min LCx occlusion and subsequent reperfusion to induce reperfused AMI (icRIPC-AMI group). In the remaining 13 pigs, a sham LAD procedure was performed by positioning the coronary guiding catheter at the LAD ostium for 60 min under general anesthesia, followed 24 h later by LCx occlusion and reperfusion (AMI group). One animal died during the sham-conditioning procedure and was replaced by another animal undergoing the same protocol. To investigate myocardial gene expression during the second window of protection, five pigs from each group were euthanized at day 3 post-AMI, while the remaining eight animals in each group were followed for 1 month (Fig. 1).

Fig. 1.

Fig. 1

Study design. icRIPC: intracardiac remote ischemic preconditioning, I/R: ischemia/reperfusion, AMI: acute myocardial infarction, LAD: left anterior descending coronary artery, LCx: left circumflex coronary artery

Experimental preparation

In accordance with ESC guidelines for human percutaneous coronary intervention (PCI) [50, 55], pigs received a loading dose of 250 mg aspirin and 300 mg clopidogrel before PCI, followed by dual antiplatelet therapy with 100 mg aspirin and 75 mg clopidogrel daily throughout the follow-up period.

For coronary angiography, pigs were premedicated with intramuscular ketamine hydrochloride (12 mg/kg), xylazine (1 mg/kg), and atropine (0.04 mg/kg). Anesthesia was induced and maintained with isoflurane delivered in oxygen, initially via face mask and subsequently after endotracheal intubation (1.5–2.5 vol% isoflurane in O₂ [1.6–1.8 L/min] with N₂O [0.5 L/min]). Under sterile conditions, the femoral artery was surgically exposed and cannulated with a 6F introducer sheath (Medtronic, Galway, Ireland). Heparin sodium (200 IU/kg) was administered before coronary angiography, which was performed using a 6F guiding catheter (Medtronic, Galway, Ireland) and iodinated contrast medium (Ultravist) (Bayer, Leverkusen, Germany). After placement of a coronary guidewire, intracoronary balloon catheter (2.75×8 mm Maverick, Boston Scientific, Marlborough, MA, USA) was placed in the mid LAD and the conditioning protocol (icRIPC) was performed. Twenty-four hours later, the coronary balloon catheter (2.75×8 mm Maverick, Boston Scientific, Marlborough, MA, USA) was advanced into the mid LCX and the reperfused AMI protocol was applied (Fig. 1). Heart rate, arterial blood pressure, ECG, oxygen saturation, and body temperature were continuously monitored throughout the procedure. After completion of angiography, the guiding catheter and introducer sheath were removed, the arteriotomy was ligated, and the surgical wound was closed in two layers.

At the predefined follow-up time points, pigs were euthanized under general anesthesia by intravenous administration of 10 mL saturated potassium chloride solution.

Blood sampling

Peripheral blood samples were collected on day −1 before and after the 3 brief LAD I/R cycles or sham procedure (pre-I/R or pre-sham I/R and post-I/R or post-sham I/R, respectively), 24 h later immediately before LCx occlusion (day 0; pre-AMI), 30 min after the onset of reperfusion (post-AMI), and 3 days after AMI. To obtain platelet-depleted plasma, EDTA-anticoagulated blood samples were centrifuged at 1,200 rpm at 4 °C for 10 min. The supernatant was transferred to a new tube and centrifuged at 1,800 rpm at 4 °C for 10 min, followed by a third centrifugation at 10,000 × g at 4 °C for 20 min. The resulting plasma was filtered through 0.8-µm Minisart® NML SFCA filters (MilliporeSigma, Göttingen, Germany) and stored at −80 °C until analysis.

Enzyme linked immunosorbent assay (ELISA)

Plasma concentrations of cardiac troponin I type 3 were measured using a commercially available ELISA kit (SEA478PO; Cloud-Clone Corp., Houston, TX, USA) according to the manufacturer’s instructions. Absorbance was measured at 450 nm using a microplate reader (SPARK, Tecan, Grödig, Austria), with background correction at 595 nm. Optical density values were converted to concentrations using a standard curve generated from calibrators with known antigen concentrations.

Tissue sampling

At the final follow-up (3 days or 1 month), myocardial tissue samples (1 cm3) were collected from predefined regions, including the infarcted LCx territory (lateral wall) and the preconditioned anterior myocardial territory distal to the site of LAD I/R or sham I/R. Samples were either fixed in 4% buffered formaldehyde or snap-frozen in liquid nitrogen and stored at −80 °C until further analysis.

Histopathology and histomorphometry of myocardial tissue samples

For histomorphometric analysis, myocardial samples (1 cm3) from the infarcted LCx territory and the preconditioned anterior region distal to the LAD I/R or sham I/R were harvested. Formalin-fixed tissues were embedded in paraffin, sectioned at 3-µm thickness, and stained with hematoxylin and eosin according to standard protocols. Histological images of the anterior and lateral myocardial walls were acquired at 4× magnification. Additionally, for each slide, 8 representative fields were analyzed at 40× magnification. In each field, 10 cardiomyocytes were manually outlined using Olympus image analysis software, and the cell circumference was recorded. For each rod-shaped cardiomyocyte, the minimum and maximum transverse diameters were measured, and their mean was calculated to obtain the mean cell diameter.

Gene expression analysis

To investigate potential cardioprotective mechanisms, four genes known to be involved in the late window of ischemic preconditioning were selected: cyclooxygenase-2 (COX2), manganese superoxide dismutase (SOD2), NADPH-dependent cytosolic aldo–keto reductase (AKR1B10), and inducible nitric oxide synthase (iNOS/NOS29 [5, 23, 32]. Additionally, five cardioprotective genes were selected based on their high expression levels in our previous experiments using three cycles of 10 min ischemia/10 min reperfusion of the mid LAD without subsequent infarction [44, 45]: C-X-C motif chemokine ligand 10 (CXCL10), SRY-box transcription factor 9 (SOX9), inhibitor of nuclear factor kappa B kinase regulatory subunit gamma (IKBKG), proliferating cell nuclear antigen (PCNA), and superoxide dismutase 1 (SOD1).

Gene expression was quantified by RT-qPCR. Total RNA was extracted from frozen myocardial samples preserved in RNAlater (QIAGEN, Hilden, Germany). Tissue samples were disrupted in QIAzol Lysis Reagent (QIAGEN) using Precellys CK28 ceramic beads (Bertin Technologies, Montigny-le-Bretonneux, France) with three homogenization cycles at 6,500 rpm, followed by RNA purification using the RNeasy kit (QIAGEN). RNA concentration was determined by NanoDrop spectrophotometry (Thermo Fisher Scientific, Waltham, MA, USA), and cDNA was synthesized using the QuantiTect Reverse Transcription Kit (Qiagen, Venlo, Netherlands). RT-qPCR was performed using QuantiFast SYBR Green PCR chemistry (Qiagen, Venlo, Netherlands) according to the manufacturer’s instructions on a CFX96 Touch Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA).

Primer pairs for AKR1B10, COX2, iNOS2, SOD2, CXCL10, SOX9, IKBKG, PCNA, and SOD1 were designed to target exonic regions of the Sus scrofa reference genome using NCBI Primer-BLAST and were synthesized by Microsynth AG (Balgach, Switzerland) (Supplementary Table S1). Target gene expression was normalized to ACTB [17, 40]. Relative gene expression changes were calculated using the ΔΔCt method and expressed as log2 fold changes (Log2FC). Primer sequences and Cq values of ACTB in the anterior and lateral myocardial territories of both groups are provided in Supplementary Table S1 and Supplementary Fig. S1.

Protein extraction and Western blot analysis

Heart tissue lysates were prepared by homogenizing 30 mg of myocardial tissue in 250 µL of 1× Laemmli Buffer prepared from 4× Laemmli Sample Buffer (Bio-Rad, Hercules, CA, USA). Homogenization was performed in Precellys CK14 lysing tubes using a Precellys 24 Lysis and Homogenization system (Bertin Technologies, Montigny-le-Bretonneux, France) for three 20-s cycles at 6,000 rpm, with cooling intervals between cycles. Samples were subsequently centrifuged at 4 °C for 15 min, and the clarified lysates were collected for Western blot analysis.

THP-1 cell lysates were used as positive and negative controls. For the positive control, THP-1 cells were stimulated with PMA (Sigma-Aldrich/Merck, Burlington, MA, USA) for 24 h, followed by culture in fresh RPMI medium (Gibco/Thermo Fisher Scientific, Waltham, MA, USA) without stimulation for an additional 24 h. Cells were subsequently stimulated with IFN-γ (PeproTech/Thermo Fisher Scientific, Waltham, MA, USA) and LPS (Sigma-Aldrich/Merck, Burlington, MA, USA) for 24 h. Negative control cells were cultured in parallel without inflammatory stimulation.

For Western blotting, equal volumes of diluted and sonicated lysates were loaded per lane. Lysates were mixed with 2 M DTT (Sigma-Aldrich/Merck, Burlington, MA, USA) and heated at 94 °C for 5 min. Proteins were separated by SDS-PAGE using 4–20% Criterion TGX Stain-Free 26-well polyacrylamide gels (Bio-Rad, Hercules, CA, USA) at 200 V for 40 min and transferred onto 0.2-µm nitrocellulose membranes using Trans-Blot Turbo Midi Transfer Packs (Bio-Rad, Hercules, CA, USA). Equal loading and transfer efficiency were assessed by stain-free gel and membrane imaging and Ponceau S staining.

Membranes were blocked for 1 h at room temperature in skim milk blocking buffer (Sigma-Aldrich/Merck, Burlington, MA, USA) prepared in PBST. Membranes were then incubated overnight at 4 °C with primary antibodies against iNOS, SOD2, and GAPDH at the following dilutions: iNOS, 1:500 (GeneTex, Irvine, CA, USA); SOD2, 1:50,000 (Proteintech, Rosemont, IL, USA); and GAPDH, 1:5,000 (Cell Signaling Technology, Danvers, MA, USA). After washing with PBST, membranes were incubated for 60 min at room temperature with the appropriate HRP-conjugated secondary antibodies: goat anti-rabbit IgG-HRP (1:10,000; Dako/Agilent, Santa Clara, CA, USA) or sheep anti-mouse IgG-HRP (1:10,000; Amersham/Cytiva, Wilmington, DE, USA). Following additional washing, chemiluminescent detection was performed using SuperSignal West Dura Extended Duration Substrate (Thermo Scientific/Thermo Fisher Scientific, Waltham, MA, USA). Signals were acquired and quantified using a ChemiDoc XRS imaging system with Image Lab software and Universal Hood II (Bio-Rad, Hercules, CA, USA). Materials used for Western blot analysis are listed in Supplementary Table S2.

Cardiac magnetic resonance imaging (CMR)

CMR with late gadolinium enhancement (CMR-LGE) was performed using a 1.5-T Siemens Avanto Syngo B17 scanner (Erlangen, Germany) equipped with a phased-array coil and vector ECG gating, as previously described [17, 59]. Cine images were acquired in standard long- and short-axis views using an ECG-gated SSFP (TrueFISP) sequence with the following parameters: TE, 1.2 ms; TR, 40 ms; 25 cardiac phases; flip angle, 50°; field of view, 360 mm; slice thickness, 8 mm; and matrix size, 256 × 256. For quantitative assessment of myocardial scar, LGE images were acquired during diastole using an inversion-recovery-prepared gradient-echo sequence 10–15 min after intravenous administration of gadolinium contrast (0.05 mmol/kg). Short- and long-axis images were acquired for comprehensive scar assessment.

Volumetric CMR measurements and visualization were performed using Segment software (version 1.9; Medviso AB, Lund, Sweden). Automatic segmentation of the LV endocardial and epicardial borders was used to derive three-dimensional volumetric measurements. End-diastolic volume (EDV), end-systolic volume (ESV), stroke volume (SV), and global LV ejection fraction (EF) were calculated automatically. IS was quantified from LGE images and expressed as a percentage of total LV mass.

Segmental contractile function was assessed using standardized 17-segment bull’s-eye plots according to the American Heart Association model [10, 52]. Segmental contraction velocity was calculated automatically [30, 33], and mean contraction velocities were determined for the infarcted lateral region (5 of 17 segments) and the conditioning anterior region (7 of 17 segments) and expressed in mm/s. All CMR-LGE analyses were performed by an experienced investigator blinded to group allocation.

Statistics

Normality of data distribution was assessed using the Shapiro–Wilk test and visual inspection of Q–Q plots. Parametric continuous variables are presented as mean±standard deviation (SD). Between-group comparisons were performed using the unpaired two-sided Student’s t test for normally distributed data. For gene expression analyses, correction for multiple comparisons was performed using the false discovery rate (FDR, Benjamini–Hochberg) method.

In accordance with the ARRIVE guidelines, a sample-size calculation was performed for the primary endpoint, IS [46]. Assuming a two-group comparison, a two-sided α of 0.05, 80% power, an expected mean IS of 15–20% of LV mass, and an SD≤4%, eight animals per group were estimated to provide sufficient power to detect an absolute between-group difference of 5.6 percentage points in IS, corresponding to a relative reduction of approximately 22–37%. No separate sample-size calculation was performed for the molecular endpoints assessed at day 3 because reliable effect-size estimates were not available. These analyses should therefore be considered exploratory and may have limited statistical power.

Statistical analyses were performed using IBM SPSS Statistics version 28 (IBM Corp., Armonk, NY, USA). Graphs were generated using GraphPad Prism version 10.6.1 (GraphPad Software, Boston, MA, USA). All tests were two-sided, and p<0.05 was considered statistically significant.

Results

Procedural data

One pig allocated to the AMI group died due to ventricular arrhythmia during the sham icRIPC procedure and was replaced by another animal undergoing the same protocol. Five pigs from each group were euthanized at the predefined 3-day follow-up, while the remaining eight animals in each group survived to the 1-month follow-up.

IS and LV function by CMR

At 3 days after AMI, CMR-LGE demonstrated a numerically lower IS in the icRIPC-AMI group than in the AMI group (15.6±3.7% vs. 18.4±4.3% of LV mass, p=0.090). In contrast, at 1 month, IS was significantly lower in the icRIPC-AMI group (8.4±3.7% vs. 14.1±1.8% of LV mass, p=0.003) (Fig. 2). LV EDV and LV ESV did not differ between groups at either 3 days or 1 month.

Fig. 2.

Fig. 2

Cardiac magnetic resonance imaging parameters on day 3 and month 1 after reperfused acute myocardial infarction (AMI) of the lateral wall for each group, with or without intracardiac remote ischemic conditioning (icRIPC applied at the anterior wall). LV EDV: left ventricular end-diastolic volume, LV ESV: left ventricular end-systolic volume, LV SV: left ventricular stroke volume, LV EF: left ventricular ejection fraction

Global LV EF was similar between groups at day 3; however, trends toward higher LV EF (p=0.052) and LV SV (p=0.069) were observed in the icRIPC-AMI group at 1 month (Fig. 2). Mean segmental contraction velocity of the anterior wall was transiently, but not significantly, lower in the icRIPC-AMI group at day 3 (Fig. 2). Segmental contraction velocity of the infarcted lateral wall was decreased in both groups at day 3, but was significantly higher in the icRIPC-AMI group than in the AMI group at 1 month (14.8±1.6 vs. 13.3±0.9 mm/s, p=0.026; ranges, 12.6–17.5 vs. 12.2–14.1 mm/s, respectively), indicating improved regional wall motion (Fig. 2). The between-group difference of 1.5 mm/s corresponded to an 11.3% higher mean contraction velocity in the infarcted lateral region, comprising 5 of the 17 LV segments (29.4%).

Histological analysis of the myocardium

Cardiomyocyte diameter and circumference did not differ between groups in either the anterior or lateral myocardial wall at 3 days or 1 month (Fig. 3 and Supplementary Fig. S2).

Fig. 3.

Fig. 3

Myocardial histology and plasma troponin I levels. A Myocyte diameter and circumference of the anterior (conditioning) and lateral (infarcted) areas at day 3 and 1 month after reperfused acute myocardial infarction (AMI) with/without delayed intracardiac remote ischemic preconditioning (icRIPC). B Serial measurements of plasma troponin I levels. C Myocardial sections of the lateral wall (infarcted area, upper panels) and anterior (conditioning areas, bottom panels) at day 3 and month 1 follow-up. 4× magnification. Blue arrow: hemorrhagic tissue, red arrow: inflammatory cell infiltration, black arrow: infiltration of a coronary microvessel by inflammatory cells resulting in a partial microvascular obstruction; green arrow: infarcted area at 1 month with the border zone of infarction; yellow arrow: partial revascularization of the infarcted area in the icRIPC group at 1 month follow-up

Analysis of cardiac enzymes

Plasma cardiac troponin I levels were elevated at day 3 after AMI, with no significant difference between the icRIPC-AMI and AMI groups (Fig. 3).

Gene expression

At 3 days after AMI, NOS2 gene expression was significantly increased in the distal anterior myocardium of the icRIPC-AMI group compared with the AMI group (Fig. 4). Among the four genes associated with delayed icRIPC, SOD2 gene expression was significantly increased in the infarcted LCx territory of the icRIPC-AMI group compared with the AMI group (Fig. 4).

Fig. 4.

Fig. 4

Selected myocardial tissue gene expressions relevant for delayed ischemic preconditioning [21] in the anterior conditioning area (ant.) and lateral wall (lat.) infarcted areas 3 days after reperfused acute myocardial infarction (AMI) with/without intracardiac remote ischemic preconditioning (icRIPC). AKR1B10: NADPH-dependent cytosolic aldo–keto reductase, NOS2: inducible nitric oxide synthase (iNOS), COX2 (cyclooxygenase-2), manganese superoxide dismutase (SOD2). Gene expression presented as Log2 fold changes (log2FC)

RT-qPCR analysis revealed no significant between-group differences in the expression of the other five selected genes in either the anterior or lateral myocardial territories (Fig. 5).

Fig. 5.

Fig. 5

Myocardial tissue gene expressions selected by relevance of ischemia/reperfusion [44, 45] in the anterior conditioning area (ant.) and lateral wall (lat.) infarcted areas 3 days after reperfused acute myocardial infarction (AMI) with/without intracardiac remote ischemic preconditioning (icRIPC). C-X-C motif chemokine ligand 10 (CXCL10), SRY-box transcription factor 9 (SOX9), inhibitor of nuclear factor kappa B kinase regulatory subunit gamma (IKBKG), proliferating cell nuclear antigen (PCNA) and superoxide dismutase 1 (SOD1)

Validation of protein expression by Western blot

Western blot analysis confirmed increased myocardial NOS2 protein expression in the conditioning anterior territory and increased SOD2 protein expression in the infarcted lateral territory of the icRIPC-AMI group at 3 days after reperfused AMI (Fig. 6).

Fig. 6.

Fig. 6

Western blot validation of significantly upregulated gene expression at the protein level 3 days after acute myocardial infarction (AMI), with/without delayed intracardiac remote ischemic preconditioning (icRIPC) of the anterior (Ant.) (conditioning) and lateral (Lat.) (infarcted) walls. A Quantitative normalized expression of manganese superoxide dismutase (SOD2) and nitric oxide synthase-2 (NOS2/iNOS: inducible nitric oxide synthase). B Representative Western blot of the lateral infarcted (upper panel) and anterior (conditioning) (bottom panel) walls. Each lane of Western blot represents a protein extract obtained from one of five animals per group. Protein expressions were normalized relative to glyceraldehyde 3-phosphate dehydrogenase (GADPH)

Discussion

The present study confirms and extends the seminal findings of Przyklenk et al. [48] on remote ischemic conditioning, which, notably, also represented a form of icRIPC, but within the first window of protection. Our findings confirm that cardioprotection can be transferred from a myocardial territory exposed to repetitive I/R to a remote myocardial territory subsequently subjected to sustained ischemia/reperfusion, resulting in reduced IS and improved regional contractile function. The present study extends the findings of Przyklenk et al. [48] in several important aspects: by using pigs, a particularly well-suited large-animal model of human reperfused AMI [29, 36], rather than dogs; by demonstrating transfer of cardioprotection from the anterior to the posterolateral myocardium rather than from the posterolateral to the anterior myocardium; by assessing myocardial function and IS using gold-standard CMR; and by demonstrating sustained cardioprotection in a longitudinal study with follow-up extending to 1 month, compared with the 4.5-h observation period in the original study. Most importantly, whereas Przyklenk et al. demonstrated immediate cardioprotection within the first window of protection, our study demonstrates that intracardiac remote cardioprotection persists when the sustained ischemic insult is initiated 24 h after the conditioning stimulus, thereby providing evidence for a delayed, second window of icRIPC.

The effects of interorgan remote pre-, per-, and post-conditioning on IS and other measures of myocardial injury have been extensively investigated, particularly when myocardial I/R occurred within the first window of protection [2, 3, 13, 37]. Experimental studies in rodents, using both ex vivo Langendorff models [9, 11, 58, 62] and in vivo models [12], have also demonstrated reductions in IS when remote ischemic conditioning, induced by transient occlusion/reperfusion of visceral or femoral arteries, was applied within the second window of protection. In contrast, large-animal studies have yielded mixed results regarding the effects of repetitive hind limb I/R on cardiac function and IS following subsequent coronary artery occlusion, predominantly investigated within the first window of protection [1, 3, 25, 37]. Importantly, only very limited preclinical evidence exists for intracardiac remote ischemic conditioning, with the seminal study by Przyklenk et al. [48] demonstrating cardioprotection within the first window of protection. Therefore, in the present study, we applied icRIPC and investigated whether intracardiac remote cardioprotection persists in the second window of protection.

At day 3, IS did not differ significantly between groups, possibly reflecting the evolving nature of acute myocardial injury, including edema, hemorrhage, and inflammation, which may influence early CMR-LGE-based assessment of IS. Although IS was significantly lower in the icRIPC-AMI group at the 1-month follow-up, only trends toward higher EF and SV were observed. This may be related to the relatively limited extent of infarction, which may not have been sufficient to result in a detectable between-group difference in global LVF [8]. Moreover, a reduction in IS does not necessarily translate directly into improved global LVF, which is additionally influenced by post-infarction remodeling [28], loading conditions, myocardial stunning [21], and coronary microvascular obstruction [20]. In contrast to global LVF, regional contractile function of the infarcted lateral wall was significantly better in the icRIPC-AMI group than in the AMI group at 1 month. According to the AHA 17-segment model [10], the analyzed lateral region comprised five segments. The mean between-group difference in contraction velocity of 1.5 mm/s corresponded to an 11.3% higher mean contraction velocity in the icRIPC-AMI group across these 5 segments, representing 29.4% of the 17 LV segments. Thus, despite the absence of a significant improvement in global LVF, the observed preservation of regional contractile function may be functionally relevant.

The significantly increased SOD2 protein expression in the infarcted territory of the icRIPC-AMI group at 3 days after AMI represents only one of several molecular and metabolic alterations that may contribute to the beneficial effects of icRIPC on IS and regional LVF. Further studies and mechanistic investigations are required to establish a causal role of SOD2 and to elucidate the underlying mechanisms of icRIPC-mediated cardioprotection.

The additional genes selected on the basis of altered expression in our previous experiments using three cycles of 10 min LAD occlusion/reperfusion without subsequent infarction did not differ significantly between groups in the present study [44, 45]. The severe myocardial injury leading to infarction may have abrogated the overexpression of these cardioprotective genes.

Pre-infarction angina pectoris (PIA) may represent a clinical correlate of icRIPC. Several clinical studies have demonstrated an association between PIA and reduced myocardial ischemic injury and adverse post-infarction remodeling. Solomon et al. [54] reported that patients experiencing chest pain within 3 months before MI had lower infarction-related CK release and less LV remodeling, although LV EF was not significantly improved. Similarly, Reiter et al. [49] demonstrated in a large cohort of ST-segment elevation (STEMI) patients undergoing primary PCI that PIA within 1 h before infarction was associated with lower CK release and improved LV EF. Schmidt et al. [51] reported reduced 30-day mortality associated with PIA, particularly when unstable angina occurred shortly before MI. Lønborg et al. [39] further demonstrated that PIA was independently associated with greater myocardial salvage assessed by CMR and reduced IS in patients with STEMI undergoing primary PCI, even after adjustment for the area at risk, suggesting that its beneficial effects extend beyond differences in the initial ischemic burden. Interestingly this study revealed no impact of collateral blood flow on the myocardial salvage with/without warming-up angina.

However, conflicting findings have been reported, highlighting ongoing controversy regarding the magnitude and consistency of the cardioprotective effects of human icRIPC [22, 35, 54]. De Luca et al. [14] and Pryds et al. [47] found no significant reduction in final IS among patients with PIA undergoing primary PCI for STEMI.

Similarly, clinical studies of interorgan RIPC have not consistently demonstrated a reduction in IS. Four cycles of 5 min upper-arm I/R applied before primary PCI for STEMI did not significantly reduce final IS in several studies [18, 47, 60]. Moreover, a history of intermittent leg ischemia before MI was associated with higher short- and long-term mortality [51], indicating that ischemic episodes in peripheral vascular disease should not necessarily be considered equivalent to experimentally induced RIPC. In contrast, a large population-based study including several thousand patients demonstrated that symptomatic ischemic atherosclerotic events originating from any arterial territory within 90 days before AMI were associated with significantly lower 7-day coronary mortality compared with patients without preceding ischemic events [19].

Several additional factors and the heterogeneity of patient populations may influence the effects of intracardiac or interorgan RIPC on outcomes after MI. Schmidt et al. [51] reported that the survival benefit associated with PIA depended on its timing as well as on clinical and angiographic characteristics, including comorbidities, particularly diabetes mellitus, pre- and post-procedural TIMI flow, door-to-needle time, concomitant medication, and infarct location. These findings indicate that the cardioprotective effects of human intracardiac and interorgan RIPC are influenced by multiple clinical factors and may therefore not be uniformly observed across different patient populations.

We acknowledge several limitations of the present study. Whereas IS and LVF were assessed at both 3 days and 1 month after AMI, gene and protein expression analyses were performed only at day 3. In addition, the sample size for the molecular analyses was relatively small. Nevertheless, after simultaneous analysis of all nine selected genes and correction for multiple testing using the FDR method, the differences in SOD2 and NOS2 expression remained statistically significant.

Gene and protein expression were assessed only at day 3, whereas the significant reduction in IS became evident at 1 month in the icRIPC-AMI group. However, early molecular responses may initiate downstream cytoprotective, reparative, and remodeling pathways whose structural and functional consequences become apparent only at later time points. Thus, the temporal dissociation between early molecular changes and the subsequent reduction in IS does not exclude a potential mechanistic contribution of these early responses. This highlights the complex biological processes, in which SOD2 is just one cog in the orchestra of reparative machinery. Nevertheless, the enhanced gene expression of SOD2 in the remotely preconditioned myocardium supports the view that I/R injury is mediated by reactive oxygen species [24] which, in turn, is attenuated by SOD2. However, the association between increased SOD2 expression and the observed reduction in IS remains inferential, and targeted mechanistic studies are required to establish causality. In contrast, increased NOS2 gene and protein expression in the anterior myocardium after the conditioning I/R stimulus is consistent with the established role of NOS2 in the late window of ischemic preconditioning [5].

Our experimental findings may have translational relevance to the cardioprotective effects of PIA in humans [22, 49], suggesting that protection induced by repeated episodes of myocardial ischemia may extend beyond the initially affected perfusion territory to remote myocardial regions and persist for at least 24 h. Furthermore, our findings suggest that, in the presence of preceding myocardial I/R, remote intracardiac myocardium may not represent a biologically neutral reference territory, as it may itself undergo adaptive molecular and functional changes associated with cardioprotection.

Supplementary Information

Below is the link to the electronic supplementary material.

Funding

Open access funding provided by Medical University of Vienna. This article is based on work supported by the COST Actions EU-CARDIOPROTECTION CA16225 and IG16225.

Data availability

All data presented in this study and supplementary information are available from the corresponding author upon reasonable request.

Declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00395-026-01208-2.

Footnotes

H. E. Bøtker, Aarhus, DK, served as guest editor for the manuscript and was responsible for all editorial decisions, including the selection of reviewers. The policy applies to all manuscripts with authors from the editor’s institution.

References

  • 1.Amanakis G, Kleinbongard P, Heusch G, Skyschally A (2019) Attenuation of ST-segment elevation after ischemic conditioning maneuvers reflects cardioprotection online. Basic Res Cardiol 114(3):22. 10.1007/s00395-019-0732-3 [DOI] [PubMed] [Google Scholar]
  • 2.Andreka G, Vertesaljai M, Szantho G, Font G, Piroth Z, Fontos G, Juhasz ED, Szekely L, Szelid Z, Turner MS, Ashrafian H, Frenneaux MP, Andreka P (2007) Remote ischaemic postconditioning protects the heart during acute myocardial infarction in pigs. Heart 93(6):749–752. 10.1136/hrt.2006.114504 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Baranyai T, Giricz Z, Varga ZV, Koncsos G, Lukovic D, Makkos A, Sárközy M, Pávó N, Jakab A, Czimbalmos C, Vágó H, Ruzsa Z, Tóth L, Garamvölgyi R, Merkely B, Schulz R, Gyöngyösi M, Ferdinandy P (2017) In vivo MRI and ex vivo histological assessment of the cardioprotection induced by ischemic preconditioning, postconditioning and remote conditioning in a closed-chest porcine model of reperfused acute myocardial infarction: importance of microvasculature. J Transl Med 15(1):67. 10.1186/s12967-017-1166-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bell RM, Basalay M, Bøtker HE, Beikoghli Kalkhoran S, Carr RD, Cunningham J, Davidson SM, England TJ, Giesz S, Ghosh AK, Golforoush P, Gourine AV, Hausenloy DJ, Heusch G, Ibanez B, Kleinbongard P, Lecour S, Lukhna K, Ntsekhe M, Ovize M, Salama AD, Vilahur G, Walker JM, Yellon DM (2022) Remote ischaemic conditioning: defining critical criteria for success-report from the 11th hatter cardiovascular workshop. Basic Res Cardiol 117(1):39. 10.1007/s00395-022-00947-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bolli R (2000) The late phase of preconditioning. Circ Res 87(11):972–983. 10.1161/01.res.87.11.972 [DOI] [PubMed] [Google Scholar]
  • 6.Botker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femmino S, Garca-Dorado D, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhäuser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schlüter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G (2018) Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol 113(5):39. 10.1007/s00395-018-0696-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bøtker HE, Kharbanda R, Schmidt MR, Bøttcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sørensen HT, Redington AN, Nielsen TT (2010) Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 375(9716):727–734. 10.1016/S0140-6736(09)620 [DOI] [PubMed] [Google Scholar]
  • 8.Bulluck H, Yellon DM, Hausenloy DJ (2016) Reducing myocardial IS: challenges and future opportunities. Heart 102(5):341–348. 10.1136/heartjnl-2015-307855 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Cai ZP, Parajuli N, Zheng X, Becker L (2012) Remote ischemic preconditioning confers late protection against myocardial ischemia-reperfusion injury in mice by upregulating interleukin-10. Basic Res Cardiol 107(4):277. 10.1007/s00395-012-0277-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS, American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the American heart association. Circulation 105(4):539–542. 10.1161/hc0402.102975 [DOI] [PubMed] [Google Scholar]
  • 11.Chen H, Jing XY, Shen YJ, Wang TL, Ou C, Lu SF, Cai Y, Li Q, Chen X, Ding YJ, Yu XC, Zhu BM (2018) Stat5-dependent cardioprotection in late remote ischaemia preconditioning. Cardiovasc Res 114(5):679–689. 10.1093/cvr/cvy014 [DOI] [PubMed] [Google Scholar]
  • 12.Chen L, Weng Y, Qing A, Li J, Yang P, Ye L, Zhu T (2022) Protective effect of remote ischemic preconditioning against myocardial ischemia-reperfusion injury in rats and mice: a systematic review and meta-analysis. Rev Cardiovasc Med 23(12):413. 10.31083/j.rcm2312413 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Consegal M, Núñez N, Barba I, Benito B, Ruiz-Meana M, Inserte J, Ferreira-González I, Rodríguez-Sinovas A (2021) Citric acid cycle metabolites predict is in pigs submitted to transient coronary artery occlusion and treated with succinate dehydrogenase inhibitors or remote ischemic perconditioning. Int J Mol Sci 22(8):4151. 10.3390/ijms22084151 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.De Luca G, Parodi G, Sciagrà R, Bellandi B, Comito V, Vergara R, Migliorini A, Valenti R, Antoniucci D (2013) Preinfarction angina does not affect IS in STEMI patients undergoing primary angioplasty. Atherosclerosis 226(1):153–156. 10.1016/j.atherosclerosis.2012.09.008 [DOI] [PubMed] [Google Scholar]
  • 15.Francis R, Chong J, Ramlall M, Bucciarelli-Ducci C, Clayton T, Dodd M, Engstrøm T, Evans R, Ferreira VM, Fontana M, Greenwood JP, Kharbanda RK, Kim WY, Kotecha T, Lønborg JT, Mathur A, Møller UK, Moon J, Perkins A, Rakhit RD, Yellon DM, Bøtker HE, Bulluck H, Hausenloy DJ (2021) Effect of remote ischaemic conditioning on IS and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy. Basic Res Cardiol 116(1):59. 10.1007/s00395-021-00896-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Gaspar A, Lourenço AP, Pereira MÁ, Azevedo P, Roncon-Albuquerque R Jr, Marques J, Leite-Moreira AF (2018) Randomized controlled trial of remote ischaemic conditioning in ST-elevation myocardial infarction as adjuvant to primary angioplasty (RIC-STEMI). Basic Res Cardiol 113(3):14. 10.1007/s00395-018-0672-3 [DOI] [PubMed] [Google Scholar]
  • 17.Gyöngyösi M, Lukovic D, Zlabinger K, Spannbauer A, Gugerell A, Pavo N, Traxler D, Pils D, Maurer G, Jakab A, Riesenhuber M, Pircher A, Winkler J, Bergler-Klein J (2020) Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. Cardiovasc Res. 10.1093/cvr/cvz192 [DOI] [PubMed] [Google Scholar]
  • 18.Hausenloy DJ, Kharbanda RK, Møller UK, Ramlall M, Aarøe J, Butler R, Bulluck H, Clayton T, Dana A, Dodd M, Engstrom T, Evans R, Lassen JF, Christensen EF, Garcia-Ruiz JM, Gorog DA, Hjort J, Houghton RF, Ibanez B, Knight R, Lippert FK, Lønborg JT, Maeng M, Milasinovic D, More R, Nicholas JM, Jensen LO, Perkins A, Radovanovic N, Rakhit RD, Ravkilde J, Ryding AD, Schmidt MR, Riddervold IS, Sørensen HT, Stankovic G, Varma M, Webb I, Terkelsen CJ, Greenwood JP, Yellon DM, Bøtker HE, CONDI-2/ERIC-PPCI Investigators (2019) Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction CONDI-2/ERIC-PPCI: a single-blind andomized controlled trial. Lancet 394(10207):1415–1424. 10.1016/S0140-6736(19)32039-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Herrett E, Bhaskaran K, Timmis A, Denaxas S, Hemingway H, Smeeth L (2014) Association between clinical presentations before myocardial infarction and coronary mortality: a prospective population-based study using linked electronic records. Eur Heart J 35(35):2363–2371. 10.1093/eurheartj/ehu286 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Heusch G (2001) Nitroglycerin and delayed preconditioning in humans: yet another new mechanism for an old drug? Circulation 103(24):2876–2878. 10.1161/01.cir.103.24.2876 [DOI] [PubMed] [Google Scholar]
  • 20.Heusch G (2019) Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol 114(6):45. 10.1007/s00395-019-0756-8 [DOI] [PubMed] [Google Scholar]
  • 23.Heusch G (2020) Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 17(12):773–789. 10.1038/s41569-020-0403-y [DOI] [PubMed] [Google Scholar]
  • 21.Heusch G (2021) Myocardial stunning and hibernation revisited. Nat Rev Cardiol 18(7):522–536. 10.1038/s41569-021-00506-7 [DOI] [PubMed] [Google Scholar]
  • 27.Heusch G, Kleinbongard P (2025) Ischaemic conditioning: a renaissance with wider perspectives? Eur Heart J 46(22):2076–2078. 10.1093/eurheartj/ehaf205 [DOI] [PubMed] [Google Scholar]
  • 29.Heusch G, Skyschally A, Schulz R (2011) The in-situ pig heart with regional ischemia/reperfusion - ready for translation. J Mol Cell Cardiol 50(6):951–963. 10.1016/j.yjmcc.2011.02.016 [DOI] [PubMed] [Google Scholar]
  • 28.Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383(9932):1933–1943. 10.1016/S0140-6736(14)60107-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Heusch G, Bøtker HE, Przyklenk K, Redington A, Yellon D (2015) Remote ischemic conditioning. J Am Coll Cardiol 65(2):177–195. 10.1016/j.jacc.2014.10.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Heusch G, Andreadou I, Bell R, Bertero E, Botker HE, Davidson SM, Downey J, Eaton P, Ferdinandy P, Gersh BJ, Giacca M, Hausenloy DJ, Ibanez B, Krieg T, Maack C, Schulz R, Sellke F, Shah AM, Thiele H, Yellon DM, Di Lisa F (2023) Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection. Redox Biol 67:102894. 10.1016/j.redox.2023.102894 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Heusch G, Bøtker HE, Ferdinandy P, Schulz R (2023) Primordial non-responsiveness: a neglected obstacle to cardioprotection. Eur Heart J 44(19):1687–1689. 10.1093/eurheartj/ehad160 [DOI] [PubMed] [Google Scholar]
  • 30.Hocum Stone LL, Swingen C, Holley C, Wright C, Chappuis E, Ward HB, McFalls EO, Kelly RF (2017) Magnetic resonance imaging assessment of cardiac function in a swine model of hibernating myocardium 3 months following bypass surgery. J Thorac Cardiovasc Surg 153(3):582–590. 10.1016/j.jtcvs.2016.10.089 [DOI] [PubMed] [Google Scholar]
  • 31.Ikonomidis I, Vlastos D, Andreadou I, Gazouli M, Efentakis P, Varoudi M, Makavos G, Kapelouzou A, Lekakis J, Parissis J, Katsanos S, Tsilivarakis D, Hausenloy DJ, Alexopoulos D, Cokkinos DV, Bøtker HE, Iliodromitis EK (2021) Vascular conditioning prevents adverse left ventricular remodelling after acute myocardial infarction: a randomised remote conditioning study. Basic Res Cardiol 116(1):9. 10.1007/s00395-021-00851-1 [DOI] [PubMed] [Google Scholar]
  • 32.Jomova K, Alomar SY, Alwasel SH, Nepovimova E, Kuca K, Valko M (2024) Several lines of antioxidant defense against oxidative stress: antioxidant enzymes, nanomaterials with multiple enzyme-mimicking activities, and low-molecular-weight antioxidants. Arch Toxicol 98(5):1323–1367. 10.1007/s00204-024-03696-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, Captur G, Francois CJ, Jerosch-Herold M, Salerno M, Teague SD, Valsangiacomo-Buechel E, van der Geest RJ, Bluemke DA (2020) Reference ranges (“normal values”) for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson 22(1):87. 10.1186/s12968-020-00683-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kleinbongard P, Arriola CG, Badimon L, Crisostomo V, Giricz Z, Gyöngyösi M, Heusch G, Ibanez B, Kiss A, de Kleijn DPV, Podesser BK, Carracedo RR, Rodríguez-Sinovas A, Ruiz-Meana M, Sanchez Margallo FM, Vilahur G, Zamorano JL, Zaragoza C, Ferdinandy P, Hausenloy DJ (2024) The improving preclinical assessment of cardioprotective therapies (IMPACT): multicenter pig study on the effect of ischemic preconditioning. Basic Res Cardiol 119(6):893–909. 10.1007/s00395-024-01083-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, Kamada T, Tada M (1993) Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 72(6):1293–1299. 10.1161/01.res.72.6.1293 [DOI] [PubMed] [Google Scholar]
  • 36.Lecour S, Andreadou I, Bøtker HE, Davidson SM, Heusch G, Ruiz-Meana M, Schulz R, Zuurbier CJ, Ferdinandy P, Hausenloy DJ (2021) IMproving preclinical assessment of cardioprotective therapies (IMPACT) criteria: guidelines of the EU-cardioprotection cost Action. Basic Res Cardiol 116(1):52. 10.1007/s00395-021-00893-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Lieder HR, Skyschally A, Sturek M, Heusch G, Kleinbongard P (2022) Remote ischemic conditioning in Ossabaw minipigs induces the release of humoral cardioprotective triggers, but the myocardium does not respond with reduced IS. Am J Physiol Heart Circ Physiol 323(6):H1365–H1375. 10.1152/ajpheart.00580.2022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Liu Z, Wang YL, Hua Q, Chu YY, Ji XM (2014) Late remote ischemic preconditioning provides benefit to patients undergoing elective percutaneous coronary intervention. Cell Biochem Biophys 70(1):437–442. 10.1007/s12013-014-9936-1 [DOI] [PubMed] [Google Scholar]
  • 39.Lønborg J, Kelbæk H, Vejlstrup N, Bøtker HE, Kim WY, Holmvang L, Jørgensen E, Helqvist S, Saunamäki K, Thuesen L, Krusell LR, Clemmensen P, Engstrøm T (2012) Influence of pre-infarction angina, collateral flow, and pre-procedural TIMI flow on myocardial salvage index by cardiac magnetic resonance in patients with ST-segment elevation myocardial infarction. Eur Heart J Cardiovasc Imaging 13(5):433–443. 10.1093/ejechocard/jer296 [DOI] [PubMed] [Google Scholar]
  • 40.Lukovic D, Gugerell A, Zlabinger K, Winkler J, Pavo N, Baranyai T, Giricz Z, Varga ZV, Riesenhuber M, Spannbauer A, Traxler D, Jakab A, Garamvölgyi R, Petnehazy Ö, Pils D, Tóth L, Schulz R, Ferdinandy P, Gyöngyösi M (2019) Transcriptional alterations by ischaemic postconditioning in a pig infarction model: impact on microvascular protection. Int J Mol Sci 20(2):344. 10.3390/ijms20020344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Marber MS, Latchman DS, Walker JM, Yellon DM (1993) Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 88(3):1264–1272. 10.1161/01.cir.88.3.1264 [DOI] [PubMed] [Google Scholar]
  • 42.Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circ 74(5):1124–1136. 10.1161/01.cir.74.5.1124 [DOI] [PubMed] [Google Scholar]
  • 43.Nygard AB, Jørgensen CB, Cirera S, Fredholm M (2007) Selection of reference genes for gene expression studies in pig tissues using SYBR green qPCR. BMC Mol Biol 8:67. 10.1186/1471-2199-8-67 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Pavo N, Lukovic D, Zlabinger K, Lorant D, Goliasch G, Winkler J, Pils D, Auer K, Ankersmit HJ, Giricz Z, Sárközy M, Jakab A, Garamvölgyi R, Emmert MY, Hoerstrup SP, Hausenloy DJ, Ferdinandy P, Maurer G, Gyöngyösi M (2017) Intrinsic remote conditioning of the myocardium as a comprehensive cardiac response to ischemia and reperfusion. Oncotarget 8(40):67227–67240. 10.18632/oncotarget.18438 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Pavo N, Lukovic D, Zlabinger K, Zimba A, Lorant D, Goliasch G, Winkler J, Pils D, Auer K, Ankersmit HJ, Giricz Z, Baranyai T, Sárközy M, Jakab A, Garamvölgyi R, Emmert MY, Hoerstrup SP, Hausenloy DJ, Ferdinandy P, Maurer G, Gyöngyösi M (2017) Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling. Sci Rep 7:43958. 10.1038/srep43958 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Würbel H (2020) The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol 18(7):e3000410. 10.1371/journal.pbio.3000410 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Pryds K, Bøttcher M, Sloth AD, Munk K, Rahbek Schmidt M, Bøtker HE (2016) Influence of preinfarction angina and coronary collateral blood flow on the efficacy of remote ischaemic conditioning in patients with ST segment elevation myocardial infarction: post hoc subgroup analysis of a randomised controlled trial. BMJ Open 6(11):e013314. 10.1136/bmjopen-2016-013314 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P (1993) Regional ischemic “preconditioning” protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 87(3):893–899. 10.1161/01.cir.87.3.893 [DOI] [PubMed] [Google Scholar]
  • 49.Reiter R, Henry TD, Traverse JH (2013) Preinfarction angina reduces IS in ST-elevation myocardial infarction treated with percutaneous coronary intervention. Circ Cardiovasc Interv 6(1):52–58. 10.1161/CIRCINTERVENTIONS.112.973164 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 37(3):267–315 [DOI] [PubMed] [Google Scholar]
  • 51.Schmidt M, Horváth-Puhó E, Pedersen L, Sørensen HT, Bøtker HE (2015) Time-dependent effect of preinfarction angina pectoris and intermittent claudication on mortality following myocardial infarction: a Danish nationwide cohort study. Int J Cardiol 187:462–469. 10.1016/j.ijcard.2015.03.328 [DOI] [PubMed] [Google Scholar]
  • 52.Selvadurai BSN, Puntmann VO, Bluemke DA, Ferrari VA, Friedrich MG, Kramer CM, Kwong RY, Lombardi M, Prasad SK, Rademakers FE, Young AA, Kim RJ, Nagel E (2018) Definition of left ventricular segments for cardiac magnetic resonance imaging. JACC Cardiovasc Imaging 11(6):926–928. 10.1016/j.jcmg.2017.09.010 [DOI] [PubMed] [Google Scholar]
  • 53.Skyschally A, Kleinbongard P, Lieder H, Gedik N, Stoian L, Amanakis G, Elbers E, Heusch G (2018) Humoral transfer and intramyocardial signal transduction of protection by remote ischemic perconditioning in pigs, rats, and mice. Am J Physiol Heart Circ Physiol 315(1):H159–H172. 10.1152/ajpheart.00152.2018 [DOI] [PubMed] [Google Scholar]
  • 54.Solomon SD, Anavekar NS, Greaves S, Rouleau JL, Hennekens C, Pfeffer MA (2004) Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling. J Am Coll Cardiol 43(9):1511–1514. 10.1016/j.jacc.2003.09.069 [DOI] [PubMed] [Google Scholar]
  • 55.Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, Van’t Hof A, Widimsky P, Zahger D (2012) Task Force on the management of ST-segment elevation acute myocardial infarction of the European society of cardiology (ESC); ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33(20):2569–2619. 10.1093/eurheartj/ehs215 [DOI] [PubMed] [Google Scholar]
  • 56.Thielmann M, Kottenberg E, Kleinbongard P, Wendt D, Gedik N, Pasa S, Price V, Tsagakis K, Neuhäuser M, Peters J, Jakob H, Heusch G (2013) Cardioprotective and prognostic effects of remote ischaemic preconditioning in patients undergoing coronary artery bypass surgery: a single-centre randomised, double-blind, controlled trial. Lancet 382(9892):597–604. 10.1016/S0140-6736(13)61450-6 [DOI] [PubMed] [Google Scholar]
  • 57.Wagner R, Piler P, Bedanova H, Adamek P, Grodecka L, Freiberger T (2010) Myocardial injury is decreased by late remote ischaemic preconditioning and aggravated by tramadol in patients undergoing cardiac surgery: a randomised controlled trial. Interact Cardiovasc Thorac Surg 11(6):758–762. 10.1510/icvts.2010.243600 [DOI] [PubMed] [Google Scholar]
  • 58.Wei M, Xin P, Li S, Tao J, Li Y, Li J, Liu M, Li J, Zhu W, Redington AN (2011) Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction. Circ Res 108(10):1220–1225. 10.1161/CIRCRESAHA.110.236190 [DOI] [PubMed] [Google Scholar]
  • 59.Winkler J, Lukovic D, Mester-Tonczar J, Zlabinger K, Gugerell A, Pavo N, Jakab A, Szankai Z, Traxler D, Müller C, Spannbauer A, Riesenhuber M, Hašimbegović E, Dawkins J, Zimmermann M, Ankersmit HJ, Marbán E, Gyöngyösi M (2020) Quantitative hybrid cardiac [18F]FDG-PET-MRI images for assessment of cardiac repair by preconditioned cardiosphere-derived cells. Mol Ther Methods Clin Dev 15(18):354–366. 10.1016/j.omtm.2020.06.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Wood G, Johnsen PH, Pedersen ALD, Frederiksen CA, Poulsen SH, Bøtker HE, Kim WY (2023) Effect of remote ischaemic conditioning on left ventricular function in ST-segment elevation myocardial infarction patients: the CONDI-2 echocardiographic sub-study. Front Cardiovasc Med 9:1054142. 10.3389/fcvm.2022.1054142 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Yellon DM, Baxter GF (1995) A “second window of protection” or delayed preconditioning phenomenon: future horizons for myocardial protection? J Mol Cell Cardiol 27(4):1023–1034. 10.1016/0022-2828(95)90071-3 [DOI] [PubMed] [Google Scholar]
  • 62.Zhang H, Li S, Jin Y (2023) Remote ischemic preconditioning-induced late cardioprotection: possible role of melatonin-mitoKATP-H2S signaling pathway. Acta Cir Bras 15(38):e380423. 10.1590/acb380423 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

All data presented in this study and supplementary information are available from the corresponding author upon reasonable request.


Articles from Basic Research in Cardiology are provided here courtesy of Springer

RESOURCES